Reconstitution of TCA cycle involving l-isoleucine dioxygenase for hydroxylation of l-isoleucine in Escherichia coli using CRISPR-Cas9

Jianhong An,Wenli Zhang,Xiaoran Jing,Yao Nie,Yan Xu
DOI: https://doi.org/10.1007/s13205-020-2160-3
IF: 2.893
2020-03-13
3 Biotech
Abstract:<span><span class="u-small-caps">l</span>-isoleucine dioxygenase (IDO) is an Fe (II)/α-ketoglutarate (α-KG)-dependent dioxygenase that specifically converts <span class="u-small-caps">l</span>-isoleucine (<span class="u-small-caps">l</span>-Ile) to (2S, 3R, 4S)-4-hydroxyisoleucine (4-HIL). 4-HIL is an important drug for the treatment and prevention of type 1 and type 2 diabetes but the yields using current methods are low. In this study, the CRISPR-Cas9 gene editing system was used to knockout <i>sucAB</i> and <i>aceAK</i> gene in the TCA cycle pathway of <i>Escherichia coli</i> (<i>E. coli</i>). For single-gene knockout, the whole process took approximately 7 days. However, the manipulation time was reduced by 2 days for each round of gene modification for multigene editing. Using the genome-edited recombinant strain <i>E. coli</i> BL21(DE3) Δ<i>sucAB</i>Δ<i>aceAK</i>/pET-28a(+)-<i>ido</i> (2Δ-<i>ido</i>), the bioconversion ratio of L-Ile to 4-HIL was enhanced by about 15% compared to <i>E. coli</i> BL21(DE3)/pET-28a(+)-<i>ido</i> [BL21(DE3)<i>-ido</i>] strain. The CRISPR-Cas9 editing strategy has the potential in modifying multiple genes more rapidly and in optimizing strains for industrial production.</span>
biotechnology & applied microbiology
What problem does this paper attempt to address?